Morningstar

PacBio to Participate in Upcoming Investor Conferences

Provided by GlobeNewswire

MENLO PARK, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences:

  • Monday, November 9, 2026: UBS Global Healthcare Conference in Palm Beach Gardens, FL. Management will participate in a fireside chat at 5:00PM ET.
  • Monday, November 16, 2026: Jefferies Global Healthcare Conference in London, UK. Management will participate in 1x1 investor meetings.
  • Wednesday, November 18, 2026: Stephens NASH26 Conference in Nashville, TN. Management will participate in a fireside chat at 3:45pm ET.

Live webcasts of the fireside chats can be accessed at the company’s investors page at investor.pacificbiosciences.com. A replay of each webcast will be available for at least 30 days following the event.

About PacBio

PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.

PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.

Contacts

Investors:
ir@pacb.com

Media:
pr@pacb.com


The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.

Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.

Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Popular

5 Stocks to Buy Trading at Big Discounts

Plus, what recent bond market volatility means for investors.
David Sekera, CFA and Sarah Hansen

2 Undervalued Stocks to Buy With Long-Term Growth Ahead

Defense spending and booming data center demand could provide powerful tailwinds for these 4-star stocks.
David Sekera, CFA, Sarah Hansen, and Jess Bebel

The Market May Be Too Pessimistic About This 4-Star Dividend Stock

Despite a looming patent cliff, a strong drug pipeline and 4.1% yield give investors reasons for optimism.
Karen Andersen, CFA

4 Stocks to Buy for the Long-Term While They’re Still Undervalued

Plus, a deep dive on SpaceX’s bid to challenge US telecoms.
David Sekera, CFA and Sarah Hansen

There Are Three Paths Forward for the AI Boom. Two of Them Lead to Lower Interest Rates

Mass layoffs or a spending slowdown would likely require hefty Fed rate cuts.
Preston Caldwell

Sponsor Center